• Home
  • About Journal
    Journal Introduction
    Editorial Board
    Youth Editorial Board
    Cooperating Institutions
    Editorial Department
  • Submission Guidelines
  • Policies & Statements
    Ethical Guidelines for Publication
    Academic Misconduct Statement
    Open Access (OA) Statement
    AIGC Use Statement
  • Journal Subscription
  • Download Center
  • 中文版
Cite this article:
DING Yaxue,ZONG Yixuan,MENG Lu,ZHANG Huidan,DING Qilong.The role of uric acid in the formation of non-alcoholic fatty liver disease[J].Journal Of Pharmaceutical Research,2022,41(4):245-250[Click to copy]
【Print this page】      【Download PDF Full Text】   【View/Add Comment】  【Download reader】  【 Close 】
←Previous|Next→ Archive    Advanced Search
This article has been viewed: 2482times   Download 2223次 QR Code for this article
Scan with your phone!
尿酸在非酒精性脂肪性肝病形成的作用
丁雅雪,宗艺璇,孟璐,张慧丹,丁启龙
Font:Larger+|Default|Smaller-
(中国药科大学药学实验教学中心,江苏 南京 211198)
摘要:
非酒精性脂肪性肝病(nonalcoholic fatty liver disease, NAFLD)作为世界上最常见的慢性肝病之一,一直是研究的热点。NAFLD与肥胖及相关代谢紊乱密切相关。高尿酸血症或高血清尿酸水平是发生在肥胖者身上常见的代谢异常。流行病学研究证实了血清尿酸水平与非酒精性脂肪肝显著相关,而黄嘌呤氧化酶(xanthine oxidase, XO)是控制尿酸合成的关键酶。本文着重对尿酸及控制其合成的限速酶XO在NAFLD形成中的作用进行综述;阐述了尿酸与代谢综合症(metabolic syndrome, MS)相关疾病之间的关系,如胰岛素抵抗、糖尿病和高血脂;最后介绍了XO抑制剂在各种疾病治疗中的应用。
关键词:  非酒精性脂肪性肝病  尿酸  黄嘌呤氧化酶  氧化应激  代谢综合征
DOI:10.13506/j.cnki.jpr.2022.04.009
基金项目:
Publication Date:April 25, 2022
The role of uric acid in the formation of non-alcoholic fatty liver disease
DING Yaxue,ZONG Yixuan,MENG Lu,ZHANG Huidan,DING Qilong
(Pharmacy Experiment Teaching Center, China Pharmaceutical University, Nanjing 211198, China)
Abstract:
As one of the most common chronic liver diseases in the world, nonalcoholic fatty liver disease (NAFLD) has always been a research hotspot. NAFLD is closely related to obesity and related metabolic disorders. Hyperuricemia or high serum uric acid levels are common metabolic abnormalities that occur in obese people. Epidemiological studies have confirmed that serum uric acid levels are significantly related to non-alcoholic fatty liver, while xanthine oxidase (XO) is a key enzyme that controls uric acid synthesis. This article focused on reviewing the role of uric acid and the rate-limiting enzyme XO in the formation of NAFLD. We also expounded the relationship between uric acid and metabolic syndrome (MS) related diseases, such as insulin resistance, diabetes, and hyperlipidemia. Finally, the application of XO inhibitors in the treatment of various diseases is introduced.
Key words:  Non-alcoholic fatty liver disease  Uric acid  Xanthine oxidase  Oxidative stress  Metabolic syndrome
Today's Visits:509    Total Visits:2383239
Website copyright:Editorial Board of Journal of Pharmaceutical Research     鲁ICP备17018036号-3     鲁公网安备 37010202001351号
Sponsored by:Shandong Institute for Food and Drug Control Shandong Pharmaceutical Association Address:No.2749 Xinluo Street,High-Tech Zone,Jinan,P.R.China Postcode:250101
Telephone Number:0531-81216586 Email :yaoxueyanjiu@163.com;yaoxueyanjiu@126.com
Technical Support:Beijing Qinyun Technology Co., Ltd.